General Information of Drug Transporter (DT)
DT ID	DTD0648 Transporter Info
Gene Name	ATP7A
Protein Name	Copper-transporting ATPase 1
Gene ID	538
UniProt ID	Q04656
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs2227291
Site of GPD	chrX:78013005 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>C
Minor Allele Frequency	G=0.7080/1401 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Docetaxel	N.A.	Sedation	Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.		[ 1]
Thalidomide	N.A.	Sedation	Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.		[ 1]
Docetaxel	N.A.	Prostatic Neoplasms	Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Prostatic Neoplasms	Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.		[ 1]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Prostatic Neoplasms	Patients with the CG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Patients with the CG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Prostatic Neoplasms	Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
Thalidomide	N.A.	Prostatic Neoplasms	Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.		[ 1]
References
1	A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. 2010 Jun;10(3):191-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.